Prasinezumab - CAS 1960462-19-4

Prasinezumab is a monoclonal antibody that selectively binds aggregated α-synuclein. Prasinezumab is under investigation as a disease-modifying therapeutic candidate for early-stage Parkinson’s disease, where it is being evaluated for its ability to interfere with pathogenic α-synuclein aggregation and progression of neurodegeneration.

Others

Others

1960439

0.975

-20°C

Ice Packs

Inhibitory Antibodies